Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Sutro Biopharma, Inc. (NASDAQ: STRO) announced that CEO Bill Newell will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 a.m. PT in San Francisco. The presentation will be accessible via the Investor Relations section of the company's website and will include an archived replay available for 30 days post-event.

Sutro specializes in innovative antibody drug conjugates (ADCs), with clinical studies for STRO-002 and STRO-001 targeting various cancers. Collaborations with companies like Bristol Myers Squibb and Merck further enhance its research portfolio.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.

About Sutro Biopharma

Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro’s platform technology also enabled the spin out of Vaxcyte and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro’s rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Investor Contact
Annie J. Chang
Sutro Biopharma
(650) 801-5728
ajchang@sutrobio.com

Media Contact
Amy Bonanno
Solebury Trout
(914) 450-0349
abonanno@soleburytrout.com

FAQ

When will Sutro Biopharma present at the J.P. Morgan Healthcare Conference?

Sutro Biopharma will present on January 12, 2023, at 11:15 a.m. PT.

Where can I watch Sutro Biopharma's presentation?

The presentation can be viewed on the Investor Relations page of Sutro Biopharma's website.

What is STRO-002 and STRO-001?

STRO-002 is an ADC targeting folate receptor alpha, while STRO-001 targets CD74, both in clinical studies for various cancers.

Who is Sutro Biopharma collaborating with on ADCs?

Sutro is collaborating with Bristol Myers Squibb, Merck KGaA, and Astellas Pharma on several ADC projects.

Is there a replay available for Sutro Biopharma's conference presentation?

Yes, an archived replay will be available for at least 30 days after the event.